Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab in primary progressive multiple sclerosis
NL-OMON50554Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Jul 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ocrelizumab in primary progressive multiple sclerosis (PPMS), sponsored by Roche. Started Jul 2012; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON50554.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50554.